Evidence map›Paper›PMID 40612873›Full record

ReviewOncology research2025

Drug discovery in advanced and recurrent endometrial cancer: Recent advances.

Alex A Francoeur, Natalie Ayoub, Danielle Greenberg, Krishnansu S Tewari

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oncology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Alex A FrancoeurDepartment of Obstetrics and Gynecology, University of California, Irvine, Orange, CA 92868, USA.
Natalie AyoubDepartment of Obstetrics and Gynecology, University of California, Irvine, Orange, CA 92868, USA.
Danielle GreenbergDepartment of Obstetrics and Gynecology, University of California, Irvine, Orange, CA 92868, USA.
Krishnansu S TewariDepartment of Obstetrics and Gynecology, University of California, Irvine, Orange, CA 92868, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endometrial cancer is the most common gynecologic cancer diagnosed in the United States and mortality is on the rise. Advanced and recurrent endometrial cancer represents a treatment challenge as historically there have been limited therapeutic options for patients. In the last several years, multiple practice-changing clinical trials have led to significant improvements in the treatment landscape. This review will cover updates in the treatment and management of advanced and recurrent endometrial cancer with a focus on novel therapeutics, such as anti-PD-L1 and PD-1 inhibitors, poly ADP-ribose polymerase (PARP) inhibitors, antibody-drug conjugates, and hormonal therapy.

Indexed as

Drug DiscoveryEndometrial NeoplasmsNeoplasm Recurrence, LocalFemaleHumansImmune Checkpoint InhibitorsPoly(ADP-ribose) Polymerase InhibitorsImmune Checkpoint InhibitorsPoly(ADP-ribose) Polymerase InhibitorsAdvanced endometrial cancerChemotherapyDrug discoveryimmunotherapyRecurrent endometrial cancerTargeted therapyTumor cancer genome atlas

Identifiers

PMID40612873
PMCPMC12215578

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.